Norvir
FDA Recall NDC 0074-3333

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.
The FDA has identified 1 recorded enforcement report(s) associated with Norvir (NDC 0074-3333). A significant event, classified as Class II, was initiated on Mar 15, 2021 by Abbvie Inc.. The reported reason for this action was: "CGMP Deviations: Intermittent exposure to temperature excursion during storage."

This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

March 2021 Class II Recall: CGMP Deviations

Recall Number
Class II Terminated
Reason for Recall
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Initiated
Mar 15, 2021
Reported
Jun 02, 2021
Quantity
362 bottles

Recall Profile & Regulatory Data

Event ID
87512
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Cardinal Health Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
FL, GA, SC
Termination Date
Jun 17, 2024
Product Description
Norvir Ritonavir Tablets 100 mg 30 Tablets Rx only NDC 0074-3333-30 Abbott Laboratories North Chicago, IL 60064, U.S.A.
Batch or Lot Expiration Information
Lot# 1131141
Affected Packages Involved in this Recall
0074-3333-30Product
0074-1940-63Product
0074-3399-30Product
0074-2340-30Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.